KarXT Concentrations in the Breast Milk and Plasma of Lactating Females

The purpose of this study is to characterize the PK of xanomeline and trospium in breast milk and plasma in healthy lactating female participants, following multiple oral administration of KarXT in healthy lactating participants.

NCT Number	NCT07257120
Lead Sponsor	Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Conditions	Healthy Volunteers
Enrollment	10 participants
Start Date	2026-01-09
Primary Completion	2026-06-08 (estimated)
Study Completion	2026-06-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-23